{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:19:04Z","timestamp":1787653144519,"version":"build-2736575974"},"reference-count":89,"publisher":"National Inquiry Services Center (NISC)","issue":"2","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["African Journal of AIDS Research"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.2989\/16085906.2026.2686719","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T07:34:06Z","timestamp":1783323246000},"page":"86-97","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["The Lenacapavir effect: Triumphalist rhetoric and the displacement of social and structural responses to HIV prevention"],"prefix":"10.2989","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0765-3613","authenticated-orcid":false,"given":"Warren","family":"Parker","sequence":"first","affiliation":[{"name":"Centre for Communication Media and Society, University of KwaZulu-Natal","place":["Durban, South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"14412","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"e_1_2_1_2_1","unstructured":"Abet T. (2026 April 21). Mad Dash for new HIV drug. What it takes to access new HIV prevention jab. Daily Monitor. https:\/\/www.monitor.co.ug\/uganda\/news\/national\/mad-dash-for-new-hiv-drug-what-it-takes-to-access-lenacapavir\u20145429950#story"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-14-S2-S2"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-025-02610-3"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.24875\/AIDSRev.25000016"},{"key":"e_1_2_1_6_1","unstructured":"AVAC. (2015) HIV prevention research & development funding trends 2000\u20132014: Investing in innovation in an evolving global health and development landscape. Retrieved from https:\/\/avac.org\/resource\/report\/hiv-prevention-research-development-funding-trends-2000-2014\/"},{"key":"e_1_2_1_7_1","unstructured":"AVAC. (2024a July 8). Global HIV Prevention Advocates Call for Accelerated Timeline for Widespread Access to Injectable Lenacapavir for PrEP. A Joint Statement. Retrieved from https:\/\/avac.org\/blog\/global-hiv-prevention-advocates-call-for-accelerated-timeline-for-widespread-access-to-twice-yearly-injectable-lenacapavir-for-prep\/"},{"key":"e_1_2_1_8_1","unstructured":"AVAC. (2024b). The gears of lenacapavir for PrEP rollout. Retrieved from https:\/\/avac.org\/wp-content\/uploads\/2024\/12\/Gears_of_LEN_Rollout_jan2025.pdf"},{"key":"e_1_2_1_9_1","unstructured":"AVAC. (2024c February 15). Coalition to accelerate access long-acting PrEP. Retrieved from https:\/\/avac.org\/resource\/coalition-to-accelerate-access-to-long-acting-prep\/"},{"key":"e_1_2_1_10_1","unstructured":"AVAC. (2025 September 24). AVAC Applauds Agreements to Accelerate Market Development for Lenacapavir for PrEP. Retrieved from https:\/\/avac.org\/blog\/avac-applauds-agreements-to-accelerate-market-development-for-lenacapavir-for-prep-calls-for-additional-commitments-to-ensure-momentum-translates-into-impact"},{"key":"e_1_2_1_11_1","unstructured":"AVAC. (2026 January 22). One year later #4: The cruel irony of lenacapavir for PrEP. https:\/\/avac.org\/blog\/cruel-irony-of-lenacapavir\/"},{"key":"e_1_2_1_12_1","unstructured":"AVAC. (2026 April 14). Three million is a step forward but not enough: AVAC and Access Bridge call for accelerated ambition and action to expand access to lenacapavir for PrEP. Retrieved from https:\/\/avac.org\/blog\/three-million-is-a-step-forward-but-not-enough\/"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.12890"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506110"},{"key":"e_1_2_1_15_1","unstructured":"Bass E. McHale T. Naimer K. Shah P. & Ladue M. (2026). Wasted investments looming crisis: The impact of U.S. global health funding cuts on HIV in South Africa. Physicians for Human Rights. https:\/\/phr.org\/wp-content\/uploads\/2026\/04\/PHR-South-Africa-Wasted-Investments-Looming-Crisis-REPORT-2026.pdf"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.2979\/2206.0"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctv125jk5c.5"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.adv2100"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2014.881519"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.56021\/9780801885846"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030449"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2007.027144"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-024-04700-1"},{"key":"e_1_2_1_25_1","unstructured":"Gilead Sciences. (2025 June 18). Yeztugo\u00ae (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection. Retrieved from https:\/\/www.gilead.com\/news\/news-details\/2025\/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection?utm_source=chatgpt.com"},{"key":"e_1_2_1_26_1","unstructured":"Global Coalition on Women and AIDS. (2006). Increase women\u2019s control over HIV prevention. Retrieved from https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/jc1237-gcwa-prevention-4_en_1.pdf"},{"key":"e_1_2_1_27_1","unstructured":"Global HIV Prevention Coalition. (2026). HIV prevention 2030. A global access framework for country-led responses. UNAIDS. https:\/\/files-hivpreventioncoalition.unaids.org\/gpc\/attachments\/2026-04-10_unaids-prevention_2030-report_web_-_v4.pdf"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(26)00033-1"},{"key":"e_1_2_1_29_1","volume-title":"Representation: Cultural representations and signifying practices","author":"Hall S.","year":"1997","unstructured":"Hall, S. (Ed.). (1997). Representation: Cultural representations and signifying practices. Sage Publications. Open University Press"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1363\/3612004"},{"key":"e_1_2_1_31_1","unstructured":"HPTN Prevention Trials Network. (2021 December 21). HPTN Studies Inform FDA\u2019s Approval of ViiV Healthcare\u2019s Long-Acting Cabotegravir Injections for HIV Prevention. Retrieved from https:\/\/www.hptn.org\/news-and-events\/press-releases\/hptn-studies-inform-fdas-approval-of-viiv-healthcares-long-acting"},{"key":"e_1_2_1_32_1","unstructured":"IAS. (2025 July). Kigali declaration. Retrieved from https:\/\/www.iasociety.org\/kigali-declaration"},{"key":"e_1_2_1_33_1","unstructured":"Institute of Human Virology. (2026 April 15). IHVN supports Nigeria\u2019s launch of lenacapavir. Retrieved from https:\/\/ihvnigeria.org\/ihvn-supports-nigerias-launch-of-lenacapavir\/"},{"key":"e_1_2_1_34_1","volume-title":"South African HIV Investment Case","author":"Jamieson L.","year":"2023","unstructured":"Jamieson, L., Meyer-Rath, G., Kubjane, M., & Johnson, L. (2023). South African HIV Investment Case. Health Economics and Epidemiology Research Office. Wits Health Consortium. University of the Witwatersrand. https:\/\/www.heroza.org\/publications\/south-african-hiv-investment-case\/"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.2307\/j.ctv16759\u00d79"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/17441692.2017.1365373"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.33590\/emjinnov\/10314103"},{"key":"e_1_2_1_39_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2013.301301"},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads1310"},{"key":"e_1_2_1_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00261-8"},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103176"},{"key":"e_1_2_1_43_1","unstructured":"Lay K. (2023 December 7). HIV vaccine trial in Africa halted after disappointing initial results. The Guardian. https:\/\/www.theguardian.com\/global-development\/2023\/dec\/07\/prepvacc-hiv-trial-africa-halted-after-disappointing-initial-results-for-combination-vaccine"},{"key":"e_1_2_1_44_1","unstructured":"Lay K. (2024 October 3). \u2018Gamechanger\u2019 HIV prevention drug to be made available cheaply in 120 countries. The Guardian. https:\/\/www.theguardian.com\/global-development\/2024\/oct\/03\/gamechanger-hiv-prevention-drug-to-be-made-available-cheaply-in-120-countries"},{"key":"e_1_2_1_45_1","unstructured":"Malan M. (2026 April 21). Our anti-HIV jab will be rolled out in 6 weeks. But funding cuts hollowed out the system needed to deliver it. Retrieved from https:\/\/bhekisisa.org\/health-news-south-africa\/2026-04-21-our-anti-hiv-jab-will-be-rolled-out-in-6-weeks-but-funding-cuts-hollowed-out-the-system-needed-to-deliver-it\/"},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269"},{"key":"e_1_2_1_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(00)00282-3"},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1071\/SH11033"},{"key":"e_1_2_1_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2025.2497902"},{"key":"e_1_2_1_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000004783"},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2003.12.002"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czad091"},{"key":"e_1_2_1_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283402c3e"},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0104-12902025250007in"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.2989\/16085906.2023.2289392"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.51644\/BAP71"},{"key":"e_1_2_1_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8603-6-23"},{"key":"e_1_2_1_58_1","unstructured":"PrEPWatch. (n.d.) Programmatic supply of injectable CAB. Retrieved from https:\/\/www.prepwatch.org\/cab-supply\/"},{"key":"e_1_2_1_59_1","doi-asserted-by":"publisher","DOI":"10.29392\/001c.30063"},{"key":"e_1_2_1_60_1","unstructured":"Resource Tracking for HIV Prevention. (2023 July). HIV prevention research & development investments 2021. Shifting investment priorities fund: Innovation in a challenging global health landscape. Retrieved from https:\/\/avac.org\/wp-content\/uploads\/2023\/08\/ResourceTrackingReport2021.pdf"},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199601000-00001"},{"key":"e_1_2_1_62_1","unstructured":"SAHPRA. (2025 October 27). SAHPRA Registers Lenacapavir. Retrieved from https:\/\/bhekisisa.org\/wp-content\/uploads\/2025\/10\/Lenacapavir-Media-Release-27-October-2025-1.pdf"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/17513057.2012.740682"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208167"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25329"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60138-9"},{"key":"e_1_2_1_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(24)00181-5"},{"key":"e_1_2_1_68_1","unstructured":"The Global Fund. (2024 December 17). PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections. Retrieved from https:\/\/www.theglobalfund.org\/en\/news\/2024\/2024-12-17-global-fund-pepfar-coordinated-effort-2-million-people-lenacapavir-prep\/"},{"key":"e_1_2_1_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000207"},{"key":"e_1_2_1_70_1","unstructured":"Uganda Ministry of Health. (2026). Lenacapavir injectable PrEP. Community Fact Sheet. https:\/\/x.com\/aidscommission\/status\/2045769699577712863\/photo\/2"},{"key":"e_1_2_1_71_1","unstructured":"UNAIDS. (2013). Smart investments. UNAIDS. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/20131130_smart-investments_en_1.pdf"},{"key":"e_1_2_1_72_1","unstructured":"UNAIDS. (2016). Prevention Gap Report. UNAIDS. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2016-prevention- gap-report_en.pdf"},{"key":"e_1_2_1_73_1","unstructured":"UNAIDS. (2024a). Driving innovations in the HIV response. UNAIDS. https:\/\/open.unaids.org\/sites\/default\/files\/2026\/2024_Infographic-Driving-Innovations.pdf"},{"key":"e_1_2_1_74_1","unstructured":"UNAIDS. (2024b). HIV response sustainability primer. UNAIDS. https:\/\/www.unaids.org\/en\/resources\/documents\/2024\/20240117_HIV_response_sustainability"},{"key":"e_1_2_1_75_1","unstructured":"UNAIDS. (2025a). AIDS crisis and the power to transform: Global AIDS update 2025. UNAIDS. https:\/\/www.unaids.org\/en\/UNAIDS-global-AIDS-update-2025"},{"key":"e_1_2_1_76_1","unstructured":"UNAIDS. (2025b). World AIDS Day report 2025. Overcoming disruption: Transforming the AIDS response. UNAIDS. https:\/\/www. unaids.org\/en\/UNAIDS-WAD-report-2025"},{"key":"e_1_2_1_77_1","unstructured":"UNAIDS. (2025c September 2024). UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need. Retrieved from https:\/\/www. unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarch ive\/2025\/september\/20250924_hiv-prevention-medicines"},{"key":"e_1_2_1_78_1","unstructured":"UNAIDS. (2025d July 15). UNAIDS welcomes new WHO guidelines on Lenacapavir. Retrieved from https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2025\/ july\/20250714_PS_WHO_Lenacapavir_Guidelines"},{"key":"e_1_2_1_79_1","unstructured":"UNAIDS. (2025f). Practical methods for projecting the costs of national strategic plans for HIV and beyond. UNAIDS. Retrieved from https:\/\/www.unaids.org\/sites\/default\/files\/2025-09\/20250918_national-strategic-plans-costing-guidelines_en.pdf"},{"key":"e_1_2_1_80_1","unstructured":"UNAIDS. (2026a March 31). New Access Framework for the new era of HIV prevention calls for scaled-up investments expanded choice and sustainability to achieve 2030 target. Retrieved from https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2026\/march\/20260331_2030_prevention_access_framework"},{"key":"e_1_2_1_81_1","unstructured":"UNAIDS. (2026b). The global AIDS strategy for 2026-2030. UNAIDS. https:\/\/www.unaids.org\/sites\/default\/files\/2026-04\/2026-2031_Global-AIDS-Strategy.pdf"},{"key":"e_1_2_1_82_1","unstructured":"UNAIDS. (2026c). What can modelling tell us about the scale-up of lenacapavir for pre-exposure prophylaxis? UNAIDS. https:\/\/www.unaids.org\/sites\/default\/files\/2025-09\/JC3154_lenacapavir-modelling_en.pdf"},{"key":"e_1_2_1_83_1","unstructured":"US Department of State. (2025 November 18). Digital press briefing on breakthrough HIV drug lenacapavir\u2019s delivery and the America First Global Health Strategy. Retrieved from https:\/\/www.state.gov\/digital-press-briefing-on-breakthrough-hiv-drug-lenacapavirs-delivery-and-the-america-first-global-health-strategy"},{"key":"e_1_2_1_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16091368"},{"key":"e_1_2_1_85_1","unstructured":"Wexler A. Kates J. Lief E. & UNAIDS. (2025 July 10). Donor Government Funding for HIV in Low- and Middle-Income Countries in 2024. KFF\/UNAIDS. https:\/\/www.kff.org\/global-health-policy\/donor-government-funding-for-hiv-in-low-and-middle-income-countries-in-2024\/"},{"key":"e_1_2_1_86_1","unstructured":"World Health Organization. (2015) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO. https:\/\/www.who.int\/publications\/i\/item\/9789241509565"},{"key":"e_1_2_1_87_1","unstructured":"World Health Organization. (2022). Guidelines on long-acting injectable cabotegravir for HIV prevention. World Health Organization. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/f3c82c5c-97c5-4651-a4c2-a909eda7eddc\/content"},{"key":"e_1_2_1_88_1","unstructured":"World Health Organization. (2024). WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: provider module for oral and long-acting PrEP. WHO. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/ac4f38b5-99d4-4fad-b32b-ab3a5475b11f\/content"},{"key":"e_1_2_1_89_1","unstructured":"World Health Organization. (2025 July 14). WHO recommends injectable lenacapavir for HIV prevention. Retrieved from https:\/\/www.who.int\/news\/item\/14-07-2025-who-recommends-injectable-lenacapavir-for-hiv-prevention"},{"key":"e_1_2_1_90_1","unstructured":"World Health Organization. (2026). Scaling innovations in public health systems: guidance and toolkit. WHO. https:\/\/www.who.int\/publications\/i\/item\/9789240120761"}],"container-title":["African Journal of AIDS Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2989\/16085906.2026.2686719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2989\/16085906.2026.2686719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:27:21Z","timestamp":1787650041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2989\/16085906.2026.2686719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.2989\/16085906.2026.2686719"],"URL":"https:\/\/doi.org\/10.2989\/16085906.2026.2686719","relation":{},"ISSN":["1608-5906","1727-9445"],"issn-type":[{"value":"1608-5906","type":"print"},{"value":"1727-9445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=raar20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=raar20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}